Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Colloidal systems for tumor targeting

G Storm1, D J Crommelin

  • 1Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands.

Hybridoma
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Local delivery of lipid-based nanoparticles containing microbial nucleic acid for osteoimmunomodulation.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025
Same author

Nanobody-liposomes as novel cancer vaccine platform to efficiently stimulate T cell immunity.

International journal of pharmaceutics·2024
Same author

Osteoimmunomodulatory GelMA/liposome coatings to promote bone regeneration of orthopedic implants.

Journal of controlled release : official journal of the Controlled Release Society·2023
Same author

Liposome induction of CD8<sup>+</sup> T cell responses depends on CD169<sup>+</sup> macrophages and Batf3-dependent dendritic cells and is enhanced by GM3 inclusion.

Journal of controlled release : official journal of the Controlled Release Society·2021
Same author

Port wine stain treatment outcomes have not improved over the past three decades.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

A technical protocol for an experimental ex vivo model using arterially perfused porcine eyes.

Experimental eye research·2019
Same journal

A monoclonal antibody specific for Pseudomonas aeruginosa amidase.

Hybridoma·2001
Same journal

Characterization of monoclonal antibodies against carcinoembryonic antigen (CEA) and expression in E. coli.

Hybridoma·2001
Same journal

Generation and characterization of monoclonal antibodies against the E6 and E7 oncoproteins of HPV.

Hybridoma·2001
Same journal

Monoclonal antibodies against human telomerase reverse transcriptase (hTERT): preparation, characterization, and application.

Hybridoma·2001
Same journal

Evaluation of clinical significance of isoferritin by development of new monoclonal antibodies specific for acidic isoferritin.

Hybridoma·2001
Same journal

Production, characterization, and epitope mapping of monoclonal antibodies against human polydeoxyribonucleotide kinase.

Hybridoma·2001
See all related articles

Liposomes offer potential for targeted cancer drug delivery but face challenges. Addressing tumor heterogeneity and drug release is crucial for effective liposomal anticancer therapies.

Area of Science:

  • Colloidal drug delivery systems
  • Nanomedicine in oncology

Background:

  • Liposomes are widely studied colloidal carriers for targeted anticancer drug delivery.
  • First-generation and second-generation (surface-modified) liposomes have distinct in vivo behaviors.

Purpose of the Study:

  • To analyze the utility of liposomal systems for tumor targeting.
  • To evaluate the in vivo fate of different liposome generations for cancer chemotherapy.
  • To discuss challenges and considerations for rational targeted liposomal drug delivery.

Main Methods:

  • Analysis of liposome behavior in vivo, including accessibility to target sites.
  • Evaluation of time- and site-controlled drug release from liposomes.
  • Review of potential target sites for liposomal drug delivery in cancer.

Related Experiment Videos

Main Results:

  • Second-generation liposomes (immunoliposomes, long-circulating liposomes) show improved targeting potential.
  • In vivo fate analysis highlights the importance of matching liposome behavior with therapeutic application.
  • Examples of cancer chemotherapy areas benefiting from liposomal delivery are provided.

Conclusions:

  • Liposomal drug delivery holds promise for cancer treatment but requires careful design.
  • Key challenges include tumor cell heterogeneity, target site accessibility, and antigen shedding.
  • Optimizing liposome-drug release at the target site is essential for clinical success.